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Background: Schistosomiasis is a significant health problem in more than 70 countries distributed between Africa,
Asia and South America, with an infection rate of one in 30 individuals. Data on Schistosomiasis, Hepatitis B virus
(HBV) and Hepatitis C virus (HCV) co-infection are scarce; however, there is a high prevalence in countries where
schistosomiasis is endemic.
Methods: A systematic search was performed on published data from 1980–2014. Published papers in the
databases Google, Medline, PubMed, and MiPc library were searched using the keywords epidemiology,
pathogenesis and outcomes of HBV, HCV and schistosomiasis and data were extracted from the relevant studies.
Results: The prevalence of HBV/schistosomiasis co-infection in countries where schistosomiasis is endemic was
high, ranging between 9.6 to approximately 64% in Egypt, and a maximum of 15.8% among hospitalized patients in
Brazil. Concurrent infection between HBV and schistosomiasis is often associated with countries where schistosomiasis
is endemic and may lead to chronic liver inflammation. Similarly, HCV infection rates in schistosomiasis populations
range from 1% in Ethiopia reaching up to 50% in Egypt.
Conclusion: There is controversy regarding the effects of HBV and HCV on schistosomiasis and vice versa. Vaccination
might be a solution to the era of schistosomiasis and co-infection with HBV and HCV.
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Schistosomiasis is a parasitic infection that is second to
malaria in prevalence and affects about 200 million
people in over 70 countries with an infection rate of one
in 30 individuals [1,2]. It is of particular importance in
Africa and South America owing to its endemicity, high
prevalence and morbidity rates in countries such as
Nigeria, Tanzania, Democratic Republic of Congo,
Ghana, and Brazil [1,3]. The prevalence of schistosomia-
sis was estimated to range between 3 to 10% in Egypt
while in Tanzania it ranges from 2.7% to 35.6% [4,5].
Schistosomiasis is a complex tropical disease caused by
Schistosoma species, of which Schistosoma haemato-
bium, S. mansoni, and S. japonicum are the most com-
mon [6]. The diverse clinical patterns of this infection
depend on the interplay of numerous factors, such as
parasite strain, host genetic background, host immunity* Correspondence: ishagadam@hotmail.com
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unless otherwise stated.and nutritional status, and co-infections [7-11]. Often,
disease progresses to an advanced stage, called hepatos-
plenic schistosomiasis (HSS), which is frequently seen in
endemic areas and is characterized by portal hyperten-
sion that may lead to gastrointestinal bleeding [12,13].
Concurrent infection between hepatitis B virus (HBV)
and schistosomiasis is often observed in countries where
schistosomiasis is endemic and might cause chronic liver
inflammation [14]. S. mansoni and HBV co-infection
pathogenesis remains controversial; however, the harm-
ful effects of S. mansoni and hepatitis C virus (HCV) co-
infection on liver fibrosis have demonstrated in endemic
countries [15-17]. Chronic HCV infection is a prevalent
chronic liver disease globally, with a burden approaching
of 185 million people testing positive for HCV antibodies
(2.8% prevalence) with the highest prevalence in North
and East Asia, the Middle East and North Africa region
(>3.5% prevalence) [18]. The three infections (schisto-
somiasis, HBV, HCV) induce acute and chronic manifes-
tations that mainly affect the liver with variable degreesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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may have an impact on disease pathophysiology which is
assessed in this article. Treatment of any of the three
conditions might impact on the other infection. For ex-
ample, in Egypt, the use of unsterile syringes during
mass campaigns of intravenous anti-schistosomiasis
treatment was suggested to be the main reason for the
spread of HCV [19]. This review was conducted to ad-
dress the gap of knowledge regarding the above men-
tioned co-infections.
Review
A systematic search of published data during the period
1980–2014was performed. Published papers on epidemi-
ology pathogenesis and outcomes of HBV and schisto-
somiasis were extracted from relevant studies provided
they are written in English or at least their abstracts are
in English. Databases were searched using different
search engines including Medline, PubMed, MiPc library
and Google with the keywords “Hepatitis B virus”,
“schistosomiasis”, “epidemiology”, “Africa”’ and “South
America” and names of particular countries where they
were entered interchangeably. We excluded articles
using serological methods to diagnose schistosomiasis.
Epidemiology of co-infection with schistosomiasis, HBV
and HCV
Published data on HBV and schistosomiasis co-infection
is scarce where we found about 15 articles fulfilling our
criteria; however, in countries where schistosomiasis is
endemic such as Egypt, a high prevalence of HBV and S.
mansoni co-infection has been described ranging from
19.6 to 33.0% [20,21]. The prevalence of co-infection
among the general population in Brazil is 15.8% [22]. A
high (58.4%) prevalence of HBV was reported among
Chinese patients with chronic schistosomiasis [23].
Similarly, published data about HCV and schistosom-
iasis co infection is scanty where only 16 articles could
fulfill our criteria. Prevalence rates of HCV infection
with wide variations as low as 1% and as high as 50%
among patients with schistosomiasis, were reported in
different countries [24-26]. Likewise high (40.2%) preva-
lence of HCV and S. mansoni antibodies were detected
among 233 wastewater treatment plants workers [27].
Interestingly, a more recent study among 3,596 Egyptian
patients found that 27.3% had both HCV-RNA and
schistosomiasis, though a weak point is their reliance on
serology to diagnose schistosomiasis, a thing that ques-
tions the association between HCV and schsitosomiasis
[28]. Nonetheless, in Yemen a group of researchers re-
ported a relationship between S. haematobium and
hepatitis B, but no correlation between S. mansoni infec-
tion and HBV or HCV [29]. The prevalence of S. man-
soni infection was 65.9% in a community-based study inEthiopia including 2,451 subjects. Moreover, the preva-
lence of schistosomal periportal thickening/fibrosis
(PPT/F) was 4.6%. At least one marker of either HBV or
HCV was detected in 43.2% of the subjects, of which
5.3% were HBsAg positive, and 1.3% were anti-HCV [30]
positive see Table 1. PPT/F increased significantly and
proportionally in terms of prevalence with community
prevalence and intensity of S. mansoni infection [30]. It
is understandable that HSS renders patients at risk of
getting HCV owing to the involvement with the risk fac-
tors for both HBV and HCV such as history of treatment
with parenteral treatment for schistosomiasis unsterile
syringes during mass campaigns, blood transfusion, sur-
gical and endoscopic interventions [21,31-35].
Immunology of schistosomiasis and hepatitis B or C
co-infection
Wahib et al., demonstrated the co-infection of HBV
and/or HCV in 120 patients with hepatosplenic schisto-
somiasis was associated with a marked depression in cell
mediated immune responses [36]. Furthermore, Edwards
et al., described the effects of hepatotropic virus co-
infection during the Th2-dominated granulomatous
phase of Schistosomal infection. They used lymphocytic
choriomeningitis virus (LCMV) as a model for hepato-
tropic viruses, and demonstrated the induction of a
strong LCMV-specific T cell response, with infiltration
of large numbers of LCMV-specific interferon (IFN)-γ-
producing CD8+ cells into the liver. This can lead to the
down regulation of Th2 cytokine production that is
dominant during S. mansoni infection and expeditious
hepatotoxicity related morbidity. Moreover, livers of co-
infected mice were highly susceptible to viral replication,
which correlated with a reduction in intrahepatic type I
IFN responses following virus infection [36-38].
HCV infection worsens the outcome of concomitant
schistosomiasis and HCV infection, causing advanced
liver disease, higher HCV RNA titers, an increase in
histological activity index, increased incidence of liver
cirrhosis and hepatocellular carcinoma, and increased
mortality rate [17,39]. S. mansoni co-infection targets a
specific subset of memory CD8+ T cells during HCV in-
fection [40]. The immune response in S. mansoni pa-
tients with or without HCV infection was evaluated by
assaying the serum levels of IFN-γ and IL-5 to estimate
cell mediated immunity and IgE levels to estimate
humoral immunity. A shift to T helper (Th)-0 and Th-2
immunity as well as an associated reduction of Th-1 re-
sponses( more or less a shift from cellular to humoral
immunity) were observed, which might have a role in
the persistence and severity of both diseases. Such im-
munity defects can lead to less HCV clearance [41,42]. S.
haematobium soluble egg antigen (SEA) affects the intra-
cellular HCV RNA burden in peripheral mononuclear
Table 1 Showing the prevalence of co-infection HCV/ HBV and hepatosplenic schistosomiasis (HSS)
Country Prevalence
of HCV/HSS
Remarks about the study Prevalence
of HBV/HSS
Remarks about the study
Egypt 33% [21] 1-Angelico et al [21] a small scale study
carried among 135 liver disease patients
19.6% [20]-33% [21] 1-El-Sayed et al [20]
This is a community based study
2-Angelico et al [21] a small scale study
carried among 135 liver disease patients
2- el-Esnawy [27] et al. carried a study
among 233 waste water treatment workers
40.2% [27]
Sudan 2.3% Mudawi et al. [25] studied 176 schistosomiasis
patients
Ethiopia 4% Berhe et al. [30] studied 199 schistosomiasis
patients
16.1% Berhe et al. [30] studied 199 schistosomiasis
patients
Brazil 12.9% Aquino et al [22] studied 101 patients with HSS 15.8% Aquino et al [22] studied 101 patients with HSS
China 0.06% Li et al. [26] studied 102 patients with schistosomiasis 58.4% Du et al. [23] studied 250 schistosomiasis patients
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chronic HCV infection, which is linked, in part, to the dir-
ect triggering of viral replication by SEA [43]. Lympho-
toxin (LT)-α contributes to inflammatory responses and
single-nucleotide polymorphisms (SNP) in the human LT-
α gene might have significant effects on individual suscep-
tibility to disease. Individuals with HCV infection alone
and those co-infected with schistosoma and HCV (but not
those infected with Schistosoma alone) were significantly
more likely to carry the LN-α gene mutation than the
control subjects [44]. The common IL-10 (−1082, −819
and −592) genotypes/haplotypes were not associated with
susceptibility to HCV infection either alone or during co-
infection with S. mansoni [45].
Impact of co-infection with schistosomiasis and HBV on
the individual disease course
Chronic infections with hepatotropic viruses, such as
HBV, can lead to liver cirrhosis, and an expected syner-
gistic effect might exacerbate hepatic pathology during
concomitant infections of HBV and schistosomiasis.
Epidemiological studies were performed to investigate
schistosomiasis/HBV co-infections, as no suitable animal
models exist. A number of studies proposed an in-
creased susceptibility to HBV caused by schistosomal in-
fections (especially the severe hepatosplenic form)
[46,47]. However, this could be explained by the frequent
need of schistosomiasis patients for blood transfusion,
especially on considering the poor infection control
measures in countries where this disease is endemic. In
contrast, other studies rejected the thesis stating any re-
lationship between schistosomiasis and HBV [48,49].
Woodchucks are susceptible to infection with both
schistosoma and woodchuck hepatitis virus (WHV) [50].
Because HBV and WHV descend from the same family
(family Hepadnaviridae), a concomitant infection of
schistosomes and WHV in woodchucks might be a suit-
able animal model for concomitant infection in humans.
However, there was no impact of schistosome infectionon WHV serum markers [51]. HBV replication was
inhibited in transgenic mice [52] during schistosomal in-
fection, where the antiviral effects of schistosomes re-
lated to IFN-γ and nitric oxide. Thus, most published
studies have found no association between schistosomia-
sis and worsening of HBV infection [53]. In contrast,
other studies described a poor prognosis of HBV when
associated with hepatosplenic schistosomiasis [17,24,54].
Interestingly HBV vaccines (both 1st and 2nd gener-
ation) can mount an immune response in schistosomia-
sis patients; however, reduced responses to vaccination
were seen in hepatosplenic schistosomiasis [37,55,56].
Therefore, further studies are needed to determine con-
clusions regarding co-infection schistosomiasis and HBV.
Impact of co-infection with schistosomiasis and HCV on
the individual disease course
S. mansoni infection increases HCV morbidity and
chronicity, which might be referred to antecedent liver
decompensation [42,57,58]. Increased HCV RNA titers,
histological activity, incidence of cirrhosis/hepatocellular
carcinoma, and higher mortality rates were noticed in
patients with co-infection [17]. However, a sample size
of 17 patients in the previous study is not big enough to
draw solid conclusions. Other studies reports found no
evidence that schistosomiasis affected the outcome of
HCV infected patients [53,59].
Impact of anti-schistosomal and anti-viral therapy on
co-infection
Praziquantel is a first line therapy for the management
and mass chemotherapy of schistosomiasis, and signifi-
cantly reduced S. mekongi infection (from 50% to 3%)
and the associated severe liver disease [60]. Because it is
administered orally, praziquantel avoids the use of nee-
dles and therefore lowers the risk of HBV and HCV
transmission in low-income countries. In a mouse
model, praziquantel improved the immunogenicity of
HBV vaccine [38]. Certain therapies used for the
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schistosomiasis co-infection [61]. In sixty-seven patients
with advanced schistosomiasis and HBV co-infection,
the use of Entecavir for 52 weeks improved liver fibrosis
markers and the Ishak fibrosis score [61]. In a mouse
model of infection with schistosomiasis, the use of pegy-
lated IFN (Peg-IFN)-a drug used in treatment of HCV-
significantly reduced the worm load in mice [62]. The
use of Peg-IFN could be considered for use in humans
to assist patients in whom the currently used oral ther-
apy has failed.
Another important issue in this context is the effect of
schistosomiasis-HCV co-infection on the response to
HCV treatment where some investigators have proposed
that co-infection retards response to this treatment [28].
However, Derbala et al. provided a rather more solid evi-
dence in their clinical trial that co-infection does not
affect the response to such therapy [63]. Measures to re-
duce the transmission of HBV and HCV by attention to
hygiene and strict hygienic practices, vaccination, early
detection in high-risk populations and treatment will be
valuable in reducing the morbidity and mortality associ-
ated with schistosomiasis co-infection.
Future prospects
As elimination of schistosomiasis is a global target, there
is a need for supplementary tools, such as vaccination,
to confer long-term prevention. Different approaches for
vaccination development have been tested in animal
models with variable immunogenicity including Biom-
phalaria alexandrina snail nucleoproteins, thyroid hor-
mone receptors and more recently, the use of DNA-Sm-
p80, and DNA-Sm14 [64-68]. The development of these
vaccines relayed mainly on using a subunit approach
where the minimal microbial constituents necessary to
surmount an appropriate immune response are incorpo-
rated into the vaccine, these constituents were tegument
proteins most of the times; nevertheless, despite the po-
tential advantages of subunit vaccines, this method re-
sulted in poorly immunogenic vaccines, a thing that
entailed the co-administration with potent adjuvants,
and in some cases, the addition of T helper epitopes to
evoke a long lasting immune response[69].
Current approaches for HCV vaccine comprise a num-
ber of approaches of which are the adoption of recom-
binant E1 and E2 proteins, manufactured peptides, viral
particles, viral vehicles, DNA vaccines, dendritic cells,
and prime-boost strategies. Nevertheless, there are a
number of problems including restricted humoral and
cell mediated responses, low transmission of likely pro-
tective viral epitopes, and low efficiency of the adjuvants
used in different protocols [70]. However, a greater un-
derstanding of co-infection and human trials are re-
quired to determine the mechanisms of vaccine-inducedimmunity, to establish a rational ground for novel vac-
cines and their optimal design. As a number of com-
bined vaccines including HBV vaccine have been proven
efficacious [71,72], a combination of HBV and a future
schistosomiasis vaccine might also prove beneficial.
Conclusion
There are few published data on schistosomiasis, HCV
and HBV co-infection. Previous studies reported a high
prevalence of HCV and HBV co-infection in countries
where schistosomiasis is endemic. The effect of HBV and
HCV on schistosomiasis and vice versa remains to be a
matter of debate. Vaccination is the most likely method
for prevention of schistosomiasis and preventing its syner-
gistic interactions by co-infection with HBV or HCV.
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